Finepoint Capital L.P. is an investment fund managing more than $376 billion ran by Stacy Vezina. There are currently 17 companies in Mrs. Vezina’s portfolio. The largest investments include Liberty Broadband Corp and Revolution Medicines Inc, together worth $138 billion.
As of 6th August 2024, Finepoint Capital L.P.’s top holding is 1,994,510 shares of Liberty Broadband Corp currently worth over $109 billion and making up 31.1% of the portfolio value.
Relative to the number of outstanding shares of Liberty Broadband Corp, Finepoint Capital L.P. owns more than 0.1% of the company.
In addition, the fund holds 729,464 shares of Revolution Medicines Inc worth $28.3 billion, whose value grew 47.9% in the past six months.
The third-largest holding is Ascendis Pharma A/S worth $25.8 billion and the next is SpringWorks Therapeutics worth $24 billion, with 638,352 shares owned.
Currently, Finepoint Capital L.P.'s portfolio is worth at least $376 billion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
The Finepoint Capital L.P. office and employees reside in Boston, Massachusetts. According to the last 13-F report filed with the SEC, Stacy Vezina serves as the General Counsel at Finepoint Capital L.P..
In the most recent 13F filing, Finepoint Capital L.P. revealed that it had increased its stake in
Liberty Broadband Corp and bought 108,250 additional shares worth around $7 million.
This means they effectively own 0.1% of the company.
Liberty Broadband Corp makes up
100.0%
of the fund's Communication Services sector allocation and has decreased its share price by approximately 0.1% in the past year.
On the other hand, Stacy Vezina disclosed a decreased stake in Sarepta Therapeutics Inc by 0.2%.
This leaves the value of the investment at $21 billion and 132,835 shares.
The two most similar investment funds to Finepoint Capital L.P. are Flagstar Advisors Inc and Marshall. They manage $352 billion and $352 billion respectively.
Finepoint Capital L.P.’s portfolio is diversified across 3 sectors.
Currently, their heaviest sector is Health Care — making up 50.8% of
the total portfolio value.
The fund focuses on investments in the United States as
58.8% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are large-cap stocks.
Stocks with a size of more than $10 billion in market cap make up
12% of the total holdings value.
On the other hand, small-cap stocks make up only 5.9% of the portfolio.
The average market cap of the portfolio companies is close to $3.73 billion.
These positions were updated on August 13th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Liberty Broadband Corp |
5.74%
1,994,510
|
$109,339,038,000 | 31.08% |
| Revolution Medicines Inc |
7.73%
729,464
|
$28,310,498,000 | 8.05% |
| Ascendis Pharma A/S |
7.74%
189,272
|
$25,812,915,000 | 7.34% |
| SpringWorks Therapeutics, Inc. |
7.73%
638,352
|
$24,046,720,000 | 6.83% |
| Argenx Se |
8.06%
54,028
|
$23,234,201,000 | 6.60% |
| Sarepta Therapeutics Inc |
16.17%
132,835
|
$20,987,930,000 | 5.97% |
| Moonlake Immunotherapeutics |
7.74%
388,835
|
$17,097,075,000 | 4.86% |
| Arvinas Inc |
6.54%
574,378
|
$15,289,942,000 | 4.35% |
| Acadia Pharmaceuticals Inc |
7.73%
905,384
|
$14,712,490,000 | 4.18% |
| Travere Therapeutics Inc |
7.73%
1,776,728
|
$14,604,704,000 | 4.15% |
| Cytokinetics Inc |
7.73%
256,449
|
$13,894,407,000 | 3.95% |
| Galapagos NV |
7.74%
542,762
|
$13,449,642,000 | 3.82% |
| Relay Therapeutics, Inc. |
7.73%
1,605,346
|
$10,466,856,000 | 2.98% |
| Prothena Corp Plc |
7.72%
433,471
|
$8,946,841,000 | 2.54% |
| EyePoint Pharmaceuticals Inc |
7.74%
707,404
|
$6,154,415,000 | 1.75% |
| Solid Biosciences Inc |
No change
961,251
|
$5,450,293,000 | 1.55% |
| Calidi Biotherapeutics Inc |
No change
125,000
|
$25,000,000 | 0.01% |
| No transactions found | |||
| Showing first 500 out of 17 holdings | |||